{"id":"NCT04760314","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-10","primaryCompletion":"2022-07-31","completion":"2023-02-01","firstPosted":"2021-02-18","resultsPosted":"2023-08-23","lastUpdate":"2023-08-23"},"enrollment":286,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis, Atopic","Dermatitis","Eczema","Skin Diseases","Skin Diseases, Genetic"],"interventions":[{"type":"DRUG","name":"Lebrikizumab","otherNames":["LY3650150"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Topical Corticosteroid","otherNames":[]}],"arms":[{"label":"Lebrikizumab 250 mg Every 4 weeks (Q4W)","type":"EXPERIMENTAL"},{"label":"Lebrikizumab 250 mg Every 2 weeks (Q2W)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.","primaryOutcome":{"measure":"Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction â‰¥2 Points From Baseline to Week 16","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Induction - Placebo","deltaMin":6.1,"sd":null},{"arm":"Induction - Lebrikizumab 250 mg Q4W","deltaMin":29.1,"sd":null},{"arm":"Induction - Lebrikizumab 250 mg Q2W","deltaMin":33.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":37,"countries":["Japan"]},"refs":{"pmids":["39442013"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/6Snw910hnAdavPQabysPCL"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":82},"commonTop":["Pyrexia","Conjunctivitis allergic","Covid-19","Nasopharyngitis","Folliculitis"]}}